OxyBridge
Pre-clinical- Indications
- Hemorrhagic shock, Organ transplantation
Company intelligence / Profile preview
VirTech Bio
Natick, Massachusetts, United Statesvirtechbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing a proprietary HBOC solution called OxyBridge™ for hemorrhagic shock and donor organ transplants. The company has secured funding for R&D, eGMP manufacture, and planned Phase 1 clinical study.
- Therapeutic areas
- ImmunologyCardiovascular
- Modalities
- Hemoglobin-based oxygen carrier (HBOC) solution
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
US Army Medical Research and Development Command (USAMRDC)US Special Operations Command (SOCOM)Medical Technology Enterprise Consortium (MTEC)
Beyond the preview
Go deeper on VirTech Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VirTech Bio.